RU2014121891A - Улучшение узнавания - Google Patents
Улучшение узнавания Download PDFInfo
- Publication number
- RU2014121891A RU2014121891A RU2014121891/15A RU2014121891A RU2014121891A RU 2014121891 A RU2014121891 A RU 2014121891A RU 2014121891/15 A RU2014121891/15 A RU 2014121891/15A RU 2014121891 A RU2014121891 A RU 2014121891A RU 2014121891 A RU2014121891 A RU 2014121891A
- Authority
- RU
- Russia
- Prior art keywords
- uridine
- composition
- vitamin
- use according
- subject
- Prior art date
Links
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract 35
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract 16
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract 16
- 229940045145 uridine Drugs 0.000 claims abstract 16
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract 10
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 9
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract 9
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract 9
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract 9
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims abstract 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract 8
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims abstract 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960001231 choline Drugs 0.000 claims abstract 7
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract 7
- 206010012289 Dementia Diseases 0.000 claims abstract 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract 5
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims abstract 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims abstract 4
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims abstract 4
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims abstract 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910019142 PO4 Inorganic materials 0.000 claims abstract 4
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract 4
- 229930003268 Vitamin C Natural products 0.000 claims abstract 4
- 229930003427 Vitamin E Natural products 0.000 claims abstract 4
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims abstract 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims abstract 4
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims abstract 4
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims abstract 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000001771 impaired effect Effects 0.000 claims abstract 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract 4
- 239000006014 omega-3 oil Substances 0.000 claims abstract 4
- 235000021317 phosphate Nutrition 0.000 claims abstract 4
- 150000003904 phospholipids Chemical class 0.000 claims abstract 4
- 229940035893 uracil Drugs 0.000 claims abstract 4
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract 4
- 239000011715 vitamin B12 Substances 0.000 claims abstract 4
- 235000019154 vitamin C Nutrition 0.000 claims abstract 4
- 239000011718 vitamin C Substances 0.000 claims abstract 4
- 235000019165 vitamin E Nutrition 0.000 claims abstract 4
- 239000011709 vitamin E Substances 0.000 claims abstract 4
- 229940046009 vitamin E Drugs 0.000 claims abstract 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract 3
- 235000011649 selenium Nutrition 0.000 claims abstract 3
- 239000011669 selenium Substances 0.000 claims abstract 3
- 229910052711 selenium Inorganic materials 0.000 claims abstract 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims abstract 2
- 208000018642 Semantic dementia Diseases 0.000 claims abstract 2
- 201000004810 Vascular dementia Diseases 0.000 claims abstract 2
- 208000010877 cognitive disease Diseases 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 239000004615 ingredient Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 206010027175 memory impairment Diseases 0.000 claims abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 229940067631 phospholipid Drugs 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 3
- 235000019152 folic acid Nutrition 0.000 claims 3
- 239000011724 folic acid Substances 0.000 claims 3
- 229960000304 folic acid Drugs 0.000 claims 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 3
- 235000019158 vitamin B6 Nutrition 0.000 claims 3
- 239000011726 vitamin B6 Substances 0.000 claims 3
- 229940011671 vitamin b6 Drugs 0.000 claims 3
- 229940087168 alpha tocopherol Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000984 tocofersolan Drugs 0.000 claims 2
- 235000004835 α-tocopherol Nutrition 0.000 claims 2
- 239000002076 α-tocopherol Substances 0.000 claims 2
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- -1 uridine phosphates Chemical class 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Применение композиции, содержащей:a. одну или несколько омега-3 жирных кислот, выбранных из группы, состоящей из докозагексаеновой кислоты (DHA), эйкозапентаеновой кислоты (EPA) и докозапентаеновой кислоты (DPA); иb. источник уридина, выбранный из уридина, дезоксиуридина, фосфатов уридина, урацила, ацилированногоуридина и цитидина;в изготовлении продукта для улучшения узнавания и/или для лечения или предупреждения нарушенной функции узнавания у субъекта.2. Применение по п. 1, в котором указанный субъект имеет один или несколько симптомов болезни Альцгеймера, умеренное когнитивное нарушение, возрастное ухудшение памяти, рассеянный склероз, сосудистую деменцию, лобновисочную деменцию, семантическую деменцию или деменцию с тельцами Леви.3. Применение по п. 1 или 2, в котором субъект представляет собой пациента с продромальной формой деменции и/или продромальной формой болезни Альцгеймера.4. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции: по меньшей мере 500 мг DHA, предпочтительно, по меньшей мере 600 мг DHA и по меньшей мере 50 мг уридина, предпочтительно, по меньшей мере 100 мг уридина.5. Применение по п. 1 или 2, в котором композиция дополнительно содержит холин, или его соли или его сложные эфиры.6. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции: 200-600 мг холина, более предпочтительно, 300-400 мг холина.7. Применение по п. 1 или 2, в котором композиция дополнительно содержит один или несколько компонентов/ингредиентов, выбранных из группы, состоящей из фосфолипидов, витамина Е, витамина С, селена, витамина B12, витамин�
Claims (16)
1. Применение композиции, содержащей:
a. одну или несколько омега-3 жирных кислот, выбранных из группы, состоящей из докозагексаеновой кислоты (DHA), эйкозапентаеновой кислоты (EPA) и докозапентаеновой кислоты (DPA); и
b. источник уридина, выбранный из уридина, дезоксиуридина, фосфатов уридина, урацила, ацилированногоуридина и цитидина;
в изготовлении продукта для улучшения узнавания и/или для лечения или предупреждения нарушенной функции узнавания у субъекта.
2. Применение по п. 1, в котором указанный субъект имеет один или несколько симптомов болезни Альцгеймера, умеренное когнитивное нарушение, возрастное ухудшение памяти, рассеянный склероз, сосудистую деменцию, лобновисочную деменцию, семантическую деменцию или деменцию с тельцами Леви.
3. Применение по п. 1 или 2, в котором субъект представляет собой пациента с продромальной формой деменции и/или продромальной формой болезни Альцгеймера.
4. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции: по меньшей мере 500 мг DHA, предпочтительно, по меньшей мере 600 мг DHA и по меньшей мере 50 мг уридина, предпочтительно, по меньшей мере 100 мг уридина.
5. Применение по п. 1 или 2, в котором композиция дополнительно содержит холин, или его соли или его сложные эфиры.
6. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции: 200-600 мг холина, более предпочтительно, 300-400 мг холина.
7. Применение по п. 1 или 2, в котором композиция дополнительно содержит один или несколько компонентов/ингредиентов, выбранных из группы, состоящей из фосфолипидов, витамина Е, витамина С, селена, витамина B12, витамина В6 и фолиевой кислоты.
8. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции:
- 50-1000 мг фосфолипидов,
- 0,5-3 мг витамина В6,
- 50-500 мкг фолиевой кислоты,
- 1-30 мкг витамина В12.
9. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции: 20-60 мг витамина Е, предпочтительно, в форме альфа-токоферола и 60-100 мг витамина С.
10. Применение по п. 1 или 2, в котором композиция содержит в суточной дозе или, предпочтительно, на 100 мл композиции:
- 100-500 мг, предпочтительно, 200-400 мг EPA,
- 1000-1500 мг, предпочтительно, 1100-1300 мг DHA,
- 50-600 мг, предпочтительно, 60-200 мг фосфолипидов,
- 200-600 мг, предпочтительно, 300-500 мг холина,
- 400-800 мг, предпочтительно, 500-700 мг монофосфатауридина,
- 20-60 мг, предпочтительно, 30-50 мг витамина Е, предпочтительно, в форме альфа-токоферола,
- 60-100 мг, предпочтительно, 70-90 мг витамина С,
- 40-80 мкг, предпочтительно, 50-70 мкг селена,
- 1-5 мкг, предпочтительно, 2-4 мкг витамина В12,
- 0,5-3 мг, предпочтительно, 0,5-2 мг витамина В6, и
- 200-600 мкг, предпочтительно, 300-500 мкг фолиевой кислоты.
11. Применение по п. 1 или 2, в котором композиция имеет в суточной дозе или, предпочтительно, на 100 мл композиции содержание энергии 50-130 ккал, содержание белка 1-10 г, содержание липидов 1-5 г и содержание усваиваемых углеводов 4-20 г.
12. Применение по п. 1 или 2, в котором субъект по краткой шкале психического статуса (MMSE) имеет оценку 20-30, в частности, 20-26, более конкретно, 24-26.
13. Применение по п. 1 или 2, в котором субъект не получает медикаментозного лечения.
14. Применение по п. 1 или 2, в котором композицию энтерально вводят пациенту по меньшей мере один раз в день в течение по меньшей мере 12 недель, предпочтительно, по меньшей мере 13 недель, более предпочтительно, по меньшей мере 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 или 24 недель.
15. Композиция, содержащая:
a. одну или несколько омега-3 жирных кислот, выбранных из группы, состоящей из докозагексаеновой кислоты (DHA), эйкозапентаеновой кислоты (EPA) и докозапентаеновой кислоты (DPA); и
b. источник уридина, выбранный из уридина, дезоксиуридина, фосфатов уридина, урацила, ацилированногоуридина и цитидина;
для применения в улучшении узнавания и/или в лечении или предупреждении нарушенной функции узнавания у субъекта.
16. Способ улучшения узнавания и/или лечения или предупреждения нарушенной функции узнавания у субъекта, причем указанный способ включает в себя введение указанному субъекту композиции, содержащей:
a. одну или несколько омега-3 жирных кислот, выбранных из группы, состоящей из докозагексаеновой кислоты (DHA), эйкозапентаеновой кислоты (EPA) и докозапентаеновой кислоты (DPA); и
b. источник уридина, выбранный из уридина, дезоксиуридина, фосфатов уридина, урацила, ацилированногоуридина и цитидина.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2011/050737 WO2013066151A1 (en) | 2011-10-31 | 2011-10-31 | Improving recognition |
NLPCT/NL2011/050737 | 2011-10-31 | ||
PCT/NL2012/050751 WO2013066165A1 (en) | 2011-10-31 | 2012-10-30 | Improving recognition |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2014121891A true RU2014121891A (ru) | 2015-12-10 |
RU2638809C2 RU2638809C2 (ru) | 2017-12-15 |
Family
ID=47144032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014121891A RU2638809C2 (ru) | 2011-10-31 | 2012-10-30 | Улучшение узнавания |
Country Status (13)
Country | Link |
---|---|
US (1) | US9763971B2 (ru) |
EP (1) | EP2773338B1 (ru) |
JP (1) | JP6272766B2 (ru) |
CN (1) | CN104039318B (ru) |
AU (1) | AU2012331689B2 (ru) |
BR (1) | BR112014010162A8 (ru) |
CA (1) | CA2853971C (ru) |
ES (1) | ES2720660T3 (ru) |
HK (1) | HK1201742A1 (ru) |
PL (1) | PL2773338T3 (ru) |
PT (1) | PT2773338T (ru) |
RU (1) | RU2638809C2 (ru) |
WO (2) | WO2013066151A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
AU2013226627B2 (en) * | 2012-03-02 | 2017-05-25 | N.V. Nutricia | Method for improving functional synaptic connectivity |
WO2015115885A1 (en) | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly |
WO2015115886A1 (en) * | 2014-01-31 | 2015-08-06 | N.V. Nutricia | Method for treating, stabilizing or slowing down brain glucose metabolism deficit |
WO2016148561A1 (en) | 2015-03-16 | 2016-09-22 | N.V. Nutricia | Method for improving bladder function |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
BR112018009288A8 (pt) | 2015-12-04 | 2019-02-26 | Nestec Sa | composições de triglicerídeos de cadeia média |
KR20180130501A (ko) * | 2016-02-22 | 2018-12-07 | 뉴트리셔스 비브이 | 신경퇴행성 질병의 예방 또는 치료를 위한 조성물 |
WO2017155386A1 (en) * | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for treating brain atrophy |
EP3443965A4 (en) | 2016-04-15 | 2020-02-19 | Hirokawa, Yoshihiro | MEANS FOR HEALING THE COGNITIVE FUNCTION |
CN108079008A (zh) | 2016-11-23 | 2018-05-29 | 上海泽生科技开发股份有限公司 | 促进胃肠系统动力的复合维生素组合物 |
CN108567792A (zh) * | 2017-03-07 | 2018-09-25 | 上海泽生科技开发股份有限公司 | 一种治疗阿尔茨海默病的复合维生素组合物 |
CN107889992A (zh) * | 2017-11-18 | 2018-04-10 | 杨越安 | 一种预防和治疗痴呆的功能保健饮料 |
CN108922292A (zh) * | 2018-07-27 | 2018-11-30 | 李明旭 | 用于延缓老年人认知能力衰退的训练方法及训练系统 |
JP7101087B2 (ja) * | 2018-09-05 | 2022-07-14 | 株式会社 伊藤園 | 軽度認知障害に対する緑茶成分の有効性評価方法 |
IT201900013707A1 (it) * | 2019-08-01 | 2021-02-01 | Cristalfarma S R L | Integratore alimentare, per uso come coadiuvante, per la prevenzione della demenza vascolare |
WO2022244727A1 (ja) * | 2021-05-17 | 2022-11-24 | 小野薬品工業株式会社 | 認知機能を改善するための組成物 |
WO2023041776A1 (en) | 2021-09-17 | 2023-03-23 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
RU2436571C2 (ru) * | 2005-05-23 | 2011-12-20 | Массачусетс Инститьют Оф Текнолоджи | Композиции, содержащие полиненасыщенные жирные кислоты (пнжк), и способы их применения |
ES2366034T3 (es) * | 2005-12-23 | 2011-10-14 | N.V. Nutricia | Composición que comprende ácidos grasos poliinsaturados, proteínas, manganeso y/o molibdeno y nucleósidos/nucleótidos para el tratamiento de la demencia. |
AU2008269728B2 (en) * | 2007-06-26 | 2013-10-31 | N.V. Nutricia | Improving memory in subjects with mini-mental state examination of 24-26 |
WO2009002148A1 (en) | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
WO2009057994A1 (en) * | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
BRPI0822111B8 (pt) * | 2007-12-20 | 2021-05-25 | Nutricia Nv | composição líquida, e, uso de uma composição líquida |
US8282335B2 (en) | 2009-06-12 | 2012-10-09 | Rs Drawings, Llc | Liftgate and mounting bracket system |
US8933217B2 (en) | 2009-07-24 | 2015-01-13 | Amazentis Sa | Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders |
WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
-
2011
- 2011-10-31 WO PCT/NL2011/050737 patent/WO2013066151A1/en active Application Filing
-
2012
- 2012-10-30 PT PT12783360T patent/PT2773338T/pt unknown
- 2012-10-30 BR BR112014010162A patent/BR112014010162A8/pt not_active IP Right Cessation
- 2012-10-30 ES ES12783360T patent/ES2720660T3/es active Active
- 2012-10-30 RU RU2014121891A patent/RU2638809C2/ru not_active IP Right Cessation
- 2012-10-30 CN CN201280065552.XA patent/CN104039318B/zh active Active
- 2012-10-30 EP EP12783360.6A patent/EP2773338B1/en not_active Revoked
- 2012-10-30 AU AU2012331689A patent/AU2012331689B2/en not_active Ceased
- 2012-10-30 US US14/355,197 patent/US9763971B2/en active Active
- 2012-10-30 WO PCT/NL2012/050751 patent/WO2013066165A1/en active Application Filing
- 2012-10-30 JP JP2014539897A patent/JP6272766B2/ja not_active Expired - Fee Related
- 2012-10-30 PL PL12783360T patent/PL2773338T3/pl unknown
- 2012-10-30 CA CA2853971A patent/CA2853971C/en not_active Expired - Fee Related
-
2015
- 2015-03-09 HK HK15102334.4A patent/HK1201742A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR112014010162A2 (pt) | 2017-06-13 |
AU2012331689B2 (en) | 2017-03-30 |
ES2720660T3 (es) | 2019-07-23 |
US9763971B2 (en) | 2017-09-19 |
CA2853971A1 (en) | 2013-05-10 |
WO2013066165A1 (en) | 2013-05-10 |
JP6272766B2 (ja) | 2018-01-31 |
PT2773338T (pt) | 2019-04-30 |
US20140274938A1 (en) | 2014-09-18 |
RU2638809C2 (ru) | 2017-12-15 |
WO2013066151A1 (en) | 2013-05-10 |
CN104039318B (zh) | 2018-05-11 |
PL2773338T3 (pl) | 2019-08-30 |
EP2773338A1 (en) | 2014-09-10 |
HK1201742A1 (en) | 2015-09-11 |
CN104039318A (zh) | 2014-09-10 |
EP2773338B1 (en) | 2019-02-06 |
JP2014534225A (ja) | 2014-12-18 |
AU2012331689A1 (en) | 2014-06-05 |
CA2853971C (en) | 2020-03-10 |
BR112014010162A8 (pt) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014121891A (ru) | Улучшение узнавания | |
US11395810B2 (en) | Memory in subjects with mini-mental state examination of 24-26 | |
KR100657642B1 (ko) | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는 오일 | |
EP2773361B1 (en) | Method for improving executive function | |
RU2014139834A (ru) | Способ улучшения функциональной синаптической связи | |
US10675292B2 (en) | Method for reducing white matter lesions, white matter hyperintensities (WMH), leukoaraiosis or periventricular white matter disease in elderly | |
EP3426237B1 (en) | Method for treating brain atrophy | |
US20240156748A1 (en) | Method for supporting memory function and/or cognitive function | |
FI3634396T3 (fi) | Koostumus L-DOPA-hoidon tehon parantamiseen | |
RU2014121888A (ru) | Композиция для улучшения оценки батареи нейропсихологических тестов | |
RU2017134335A (ru) | Способ улучшения функции мочевого пузыря |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201031 |